Biomarkers in cervical precancer management: The new frontiers

Future Oncology

Volumn 4, Issue 4, 2008, Pages 515-524

  Khan, Ashfaq M ^a,b   Singer, Albert ^a  

^a WHITTINGTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarkers; Cervical precancer; Cervical screening; Molecular markers

Indexed keywords

BIOLOGICAL MARKER; CELL CYCLE PROTEIN 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E; CYCLINE; GENE PRODUCT; KI 67 ANTIGEN; MESSENGER RNA; MINICHROMOSOME MAINTENANCE PROTEIN 2; MINICHROMOSOME MAINTENANCE PROTEIN 4; MINICHROMOSOME MAINTENANCE PROTEIN 5; MINICHROMOSOME MAINTENANCE PROTEIN 6; MINICHROMOSOME MAINTENANCE PROTEIN 7; MONOCLONAL ANTIBODY KI 67; PROTEIN E4; PROTEIN E6; PROTEIN E7; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR POU4F1; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

CANCER GRADING; CANCER SCREENING; DIAGNOSTIC ACCURACY; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VIRUS INFECTION; WART VIRUS;

ALPHAPAPILLOMAVIRUS; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA PROBES, HPV; DNA, VIRAL; FEMALE; FORECASTING; HUMANS; NEOPLASM PROTEINS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RNA, MESSENGER; RNA, NEOPLASM; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; UTERINE CERVICITIS;

EID: 55349143823     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.4.515     Document Type: Review

References (106)

1. Sasieni P, Cuzick J, Farmery E: Accelerated decline in cervical cancer mortality in England and Wales. Lancet 346 (8989), 1566-1567 (1995).
2. Evaluation and Monitoring of Servening Programmes. Sankila R, Demaret E, Hakama M, Lynge E, Schouten LJ, Parkin DM (Eds). European Commission, Europe Against Cancer Programme, Brussels, Belgium (2001).
3. Peto J, Gilham C, Fletcher O, Matthews FE: The cervical cancer epidemic that screening has prevented in the UK. Lancet 364 (9430), 249-256 (2004).
4. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F: WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol. 6(4), 204 (2005).
5. Karl M, Peter MH: Human papilloma virus immortalization and transformation functions. Virus Research 89, 213-228 (2002).
6. Deligeorgi-Politi H, Mui KK, Trotta K et al.: Immunocytochemical localization of human papilloma virus and cytomorphologic correlation in smears and biopsies of cervical flat condylomata. Diagn. Cytopathol. 2, 320-325 (1986).
7. Syrjänen KJ, Pyrhönen S: Immunoperoxidase demonstration of human papilloma virus (HPV) in clysplastic lesions of the uterine cervix. Arch. Gynecol. 233(1), 53-61 (1982).
8. Parkkinen S, Mäntyjärvi R, Syijänen K, Ranki M: Detection of human papillomavirus DNA by the nucleic acid sandwich hybridization method from cervical scraping. J. Med. Virol. 20(3), 279-288 (1986).
9. Okagaki T, Twiggs LB, Zachow KR, Clark BA, Ostrow RS, Faras AJ: Identification of human papillomavirus DNA in cervical and vaginal intraepithelial neoplasia with molecularly cloned virus-specific DNA probes. Int. J. Gynecol. Pathol. 2(2), 153-159 (1983).
10. Farthing A, Masterson P, Mason WP. Vousden KH: Human papillomavirus detection by hybrid capture and its possible clinical use. J. Clin. Pathol. 47(7), 649-652 (1994).
11. Gregoire L, Arella M, Campione-Piccardo J, Lancaster WD: Amplification of human papillomavirus DNA sequences by using conserved primers. J. Clin. Microbiol. 27(12), 2660-2665 (1989).
12. Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ: The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol. 76(Pt 4), 1067-1062 (1995).
13. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J: Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high grade CIN. An update of pooled evidence. Gynecol. Oncol. 99(Suppl. 3), 7-11 (2005).
14. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J: Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24 (S3), 78-79 (2006).
15. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: Consensus guidelines for the management of women with abnormal cervical cancer screening tests. American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference 2006. Am. J. Obstet. Cynecol. 197(4), 346-355 (2007).
16. Kjaer S, Hogdall E, Frederiksen K et al.: The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 66, 10630-10636 (2006).
17. Khan MJ, Castle PE, Lorincz; AT et al.: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97, 1072-1079 (2005).
18. Wright TC, Schiffman M, Solomon D et al.: Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 103,304-309 (2004).
19. Arbyn M, Buntinx F, van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J: Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J. Natl Cancer Inst 96(4), 280-289 (2004).
20. ASCUS-LSIL Triage Study (ALTS) Group: Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am. J, Obstet. Gynecol. 188(6), 1383-1392 (2003).
21. Sherman ME, Schiffman M, Cox JT; ASCUS-LSIL Triage Study (ALTS) Group: Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/ Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J. Natl Cancer Inst. 94, 102-107 (2002).
22. Bruner KS, Davey DD: ASC-US and HPV testing in women aged 40 years and over Diagn. Cytopathol. 31, 358-361 (2004).
23. Bigrigg MA, Codling BW, Pearson P et al.: Colposcopic diagnosis and treatment of cervical dysplasia at a single clinic visit. Lancet 306, 229-231 (1990).
24. Dobbs SP, Asmussen T, Nunns D et al.: Does histological incomplete excision of cervical intraepithelial neoplasia following large loop excision of transformation zone increase recurrence rates? A six-year cytological follow up. Br. J. Obstet. Gynaecol. 107, 1298-1301 (2000).
25. Chew GK, Jandial L, Paraskevaidis E et al.: Pattern of CIN recurrence following laser ablation treatment on long term follow up. Int. J. Gynecol. Cancer 9, 487-490 (1999).
26. Flannelly G, Langhan H, Jandial L et al.: A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. Br. J. Obstet. Gynaecol. 104 (6), 718-722 (1997).
27. Paraskevaidis E, Arbyn M, Sotiriadis A et al.: The role of HPV DNA testing in the follow-up period after treatment for CIN. A systematic review of the literature. Cancer Teat. Rev. 30(2), 205-211 (2004).
28. Stanley MA: Human papillomavirus and cervical carcinogenesis. Best Pract. Res. Clin. Obstet Gynaecol. 15, 663-676 (2001).
29. Hudson JB, Bedell MA, McCance DJ. Laiminis LA: Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J. Virol. 64, 519-526 (1990).
30. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R: The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63, 4417-4421 (1989).
31. Kraus I, Molden T, Holm R et al.: Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J. Clin. Microbiol. 44(4), 1310-1317 (2006).
32. + when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int. J. Cancer 114(6), 973-976 (2005).
33. Molden T, Kraus I, Karlsen F, Skomedal H, Nygård JF, Hagmar B: Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4, 136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol. Biomarkers Prev. 14(2), 367-372 (2005).
34. Doorbar J, Campbell D, Grand RJ, Gallimore PH: Identification of the human papilloma virus- 1a E4 gene products. EMBO J. 5, 355-362 (1986).
35. Doorbar J, Ely S, Sterling J, Mclean C, Crawford L: Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature 352, 824-827 (1991).
36. Doorbar J: Papillomavirus life cycle organization and biomarker selection. Disease Markers 23, 297-313 (2007).
37. Crum CP, Nuovo G, Friedman D, Silverstein SJ: Accumulation of RNA homologous to human papillomavirus type 16 open reading frames in genital precancers. J. Virol. 62(1), 84-90 (1988).
38. Stoler MH, Wolinsky SM, Whitbeck A, Broker TR, Chow LT: Differentiation-linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridization with message-specific RNA probes. Virology 172(1), 331-340 (1989).
39. Nakahara T, Nishimura A, Tanaka M, Ueno T, Ishimoto A, Sakai H: Modulation of the cell division cycle by human papillomavirus type 18 E4. J. Virol. 7621), 10914-10920 (2002).
40. Cook JG, Park CH, Burke TW et al.: Analysis of Cdc6 function in the assembly of mammalian prereplication complexes. Proc. Natl Acad. Sci. USA 99(3), 1347-1352 (2002).
41. Shin JH, Grabowski B, Kasiviswanathan R et al.: Regulation of minichromosome maintenance helicase activity by Cdc6. J Biol. Chem. 278(39), 38059-38067 (2003).
42. Stillman B: Cell cycle control of DNA replication. Science 274 (5293), 1659-1664 (1996).
43. Romanowski P, Madine M: Mechanisms restricting DNA replication to once per cell cycle: the role of Cdc6p and ORC. Trends Cell Biol.. 7(1), 9-10 (1997).
44. Newlon CS: Putting it all together: building a prereplicative complex. Cell 91, 717-720 (1997).
45. Botchan M: Coordinating DNA replication with cell division: current status of the licensing concept. Proc. Natl. Acad. Sci. USA 93, 9997-10000(1996).
46. Romanowski P, Madine MA: Mechanisms restricting DNA replication to once per cell cycle: MCMS, pre-replicative complexes and kinases. Trend Cell. Biol. 6, 184-188 (1996).
47. Williams GH, Romanowski P, Morris L et al.: Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc. Natl Acad. Sci. USA 99, 14932-14937 (1998).
48. Freeman A, Morris LS, Mills AD et al.: Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin. Cancer Res. 5(8), 2121-2132 (1999).
49. Murphy N, Ring M, Heffron CC et al.: Quantitation of CDC6 and MCM5 mRNA in cervical intraepithelial neoplasia, and invasive squamous cell carcinoma of the cervix. Mod. Pathol. 186), 844-849 (2005).
50. Brake T, Connor JR Petereit DG et al.: Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: identification of minichromosome maintenance protein 7 as an informative biomarker for human cervical cancer. Cancer Res. 63(23), 8173-8180 (2003).
51. Chen Y, Miller C, Mosher R et al.: Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res. 63, 1927-1935 (2003).
52. Santin AD, Fenghuang Z, Bignotti E et al.: Gene expression profiles of primary HPV-16 and HPV-18 infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 331, 269-291 (2005).
53. Freeman A, Morris LS, Mills AD: Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin. Cancer Res. 5, 2121-2132 (1999).
54. Murphy N, Ring M, Heffron CC et al.: Quantitation of CDC6 and MCM5 mRNA in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Mod Pathol. 18(6), 844-849 (2005).
55. Verrijzer CP, van der Vliet PC: POU domain transcription factors. Biochim. Biophys. Acta 1173, 1-21 (1993).
56. Wegner M, Drolet DW Rosenfeld MG: POU-domain proteins. Structure and function of developmental regulators. Curr. Opin. Cell Biol. 5, 488-498 (1993).
57. Gerrero MR, McEvilly RJ, Turner E et al.: Brn-3.0, a POU domain protein expressed in the sensory, immune and endocrine systems that functions on elements distinct from known octamer motifs. Proc. Natl Acad. Sci. USA 90, 10841-10845 (1993).
58. Lillycrop KA, Budhram-Mahadeo VS, Lakin ND et al.: A novel POU family transcription factor is closely related to Bm-3 but has a distinct expression pattern in neuronal cells. Nucleic Acids Res. 20, 5093-5096 (1992).
59. Turner EE, Jenne KJ, Rosenfeld MG: Brn-3.2: a Brn-3-related transcription factor with distinctive central nervous system expression and regulation by retinoic acid. Neuron 12, 205-218 (1994).
60. Dent CL, McIndoe GAJ, Latchman DS: The constitutively expressed octamer binding protein OTF-1 and a novel octamer binding protein expressed specifically in cervical cells bind to an octamer-related sequence in the human papillomavirus 16 enhancer. Nucleic Acids Res. 19, 4531-4535 (1991).
61. Morris PJ, Dent CL, Ring CJA et al.: The octamer-binding site in the HPV16 regulatory region produces opposite effects on gene expression in cervical and non-cervical cells. Nucleic Acids Res. 21, 1019-1023 (1993).
62. Ndisang D, Budhram-Mahadeo VS, Latchman DS: The Brn-3a transcription factor plays a critical role in regulating HPV gene expression and determining the growth characteristics of cervical cancer cells. J. Biol. Chem. 274, 28521-28527 (1999).
63. Ndisang D, Budhram-Mahadeo V, Pedley B et al.: The Bm-3a transcription factor plays a key role in regulating the growth of cervical cancer cells. Oncogene 20, 4899-4903 (2001).
64. Ndisang D, Morris PJ, Chapman C et al.: The HPV activating transcription factor Brn-3a is over expressed in CIN3 lesions. J. Clin. Invest. 101, 1687-1692 (1998).
65. Sindos M, Ndisang D, Pisal N et al.: Measurement of Brn-3a levels in Pap smears provides a novel diagnostic marker for the detection of cervical neoplasia. Gynecol. Oncol. 90, 366-371 (2003).
66. Bravo R, Frank R, Blundell PA et al.: Cyclin/PCNA is the auxiliary protein of DNA polymerase-δ. Nature 326 (6112), 515-517 (1987).
67. Garcia RL, Coltrera MD, Gown AM: Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. Am. J. Pathol. 134(4), 733-739 (1989).
68. Shurbaji MS, Brooks SK, Thurmond TS: Proliferating cell nuclear antigen immunoreactivity in cervical intraepithelial neoplasia and benign cervical epithelium. Am. J. Clin. Pathol. 100(1), 22-26 (1993).
69. Mittal KR Demopoulos RI, Goswami S; Proliferating cell nuclear antigen (cyclin) expression in normal and abnormal cervical squamous epithelia. Am. J. Surg. Pathol. 17(2), 117-122 (1993).
70. Raju GC: Expression of the proliferating cell nuclear. antigen in cervical neoplasia. Int. J Gynecol. Pathol. 13(4), 337-341 (1994).
71. Gerdes J, Lemke H, Baisch H et al.: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133(4), 1710-1715 (1984).
72. Garzetti GG, Clavattini A, de Nictolis M et al.: MIB 1 immunostaining in cervical intraepithelial neoplasia: prognostic significance in mild and moderate lesions. Gynecol. Obstet. Invest. 42 (4), 261-266 (1996).
73. Dunton CJ, van Hoeven KH, Kovatich AJ et al.: Ki-67 antigen staining as an adjunct to identifying cervical intraepithelial neoplasia. Gynecol. Oncol. 64(3), 451-455 (1997).
74. Resnick M, Lester S, Tate JE, Sheets EE, Sparks C, Crum CP: Viral and histopathologic correlates of MN and MIB-1 expression in cervical intraepithelial neoplasia. Hum. Pathol. 27(3), 234-239 (1996).
75. Konishi I, Fujii S, Nonogaki H et al.: Immunohistochemical analysis of estrogen receptors, progesterone receptors, Ki-67 antigen, and human papillomavirus DNA in normal and neoplastic epithelium of the uterine cervix. Cancer 68(6), 1340-1350 (1991).
76. Lees E, Faha B, Dulic V et al.: Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner. Genes Dev. 6(10), 1874-1885 (1992).
77. Cho NH, Kim YT, Kim JW: Correlation between G1 cyclins and HPV in the uterine cervix. Int. J Gynecol. Pathol. 16(4), 339-347 (1997).
78. Dellas A, Schultheiss E, Leivas MR et al.: Association of p27Kip1, cyclin E and c-myc expression with progression and prognosis In HPV-positive cervical neoplasms. Anticancer Res. 18(6A), 3991-3998 (1998).
79. Quade BJ, Park JJ, Crum CP et al.: In vivo cyclin E expression as a marker for early cervical neoplasia. Modern Pathol. 11 (12), 1238-1246 (1998).
80. Tae Kim Y, Kyoung Choi E, Hoon Cho N et al.: Expression of cyclin E and p27 (KIP1) in cervical carcinoma. Cancer Lett. 153(1-2), 41-50 (2000).
81. Keating JT, Cviko A, Riethdorf S et al.: Ki-67, cyclin E, and p16INK4 are complementary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am. J. Surg. Pathol. 25(7), 884-891 (2001).
82. Sakaguchi M, Fujii Y, Hirabayashi H et al.: Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int. J. Cancer 65, 442-445 (1996).
83. Akanuma D, Uzawa N, Yoshida MA et al.: Inactivation patterns of the p16 (INK4a) gene in oral squamous cell carcinoma cell lines. Oral Oncology 35(5), 476-483 (1999).
84. Sano T, Oyama T, Kashiwabara K et al.: Over expression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol. Int. 48, 580-588 (1998).
85. Klaes R, Friedrich T, Spitkovsky D et al.: Over expression of p16 as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int. J. Cancer 92, 276-284 (2001).
86. Saqi A, Pasha TL, McGrath CM et al.: Over expression of p16INK4A in liquid-based specimens (SurePath) as a marker of cervical dysplasia and neoplasia. Diagn. Cytopathol. 27(6), 365-370 (2002).
87. Bibbo M, DeCecco J, Kovatich AJ: Pl6INK4a as an adjunct test in liquid based cytology. Anal. Quant. Cytol. Histol. 25(1), 8-11 (2003).
88. Negri G, Egarter-Vigl E, Kasal A et al.: p16INK4a is a useful marker for the diagnosis of the cervix uteri and its precursors: an immunohistological study with immunocytochemical correlations. Am. J. Surg. Pathol. 27(2), 187-193 (2003).
89. Murphy N, Ring M, Killalea AG et al.: P16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep™ smears. J. Clin. Pathol. 56, 53-63 (2003).
90. Pientong C, Ekalaksananan T, Swadpanich U et al.: Immunocytochemical detection of p16INK4a protein in scraped cervical cells. Acta Cytologica 47(4), 616-623 (2003).
91. Queiroz C, Silva TC, Alves VA et al.: P16 (INK4a) expression as a potential prognostic marker in cervical pre-neoplastic and neoplastic lesions. Pathol. Res. Pract. 202(2), 77-83 (2006).
92. Dray M, Russell P, Dalrymple C et al.: P16 (INK4a) as a complementary marker of high-grade intraepithelial lesions of the uterine cervix. Experience with squamous lesions in 189 consecutive cervical biopsies. Pathology 37(2), 112-124 (2005).
93. Milde-Langosch K, Hagen M, Bamberger AM et al.: Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. Virchow's Archive 439(1), 55-61 (2001).
94. Meyerson M, Counter CM, Eaton EN et al.: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90(4), 785-795 (1997).
95. Kim NW, Piatyszek MA, Prowse KR et al.: Specific association of human telomerase activity with immortal cells and cancer. Science 266(5193), 2011-2015 (1994).
96. Feng J, Funk WD, Wang SS et al.: The RNA component of human telomerase. Science 269(5228), 1236-1241 (1995).
97. Nakamura TM, Morin GB, Chapman KB et al.: Telomerase catalytic subunit homologs from fission yeast and human. Science 277(5328), 955-998 (1997).
98. Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M: Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancec Res. 58(7), 1558-1561 (1998).
99. Wisman GB, de Jong S, Meersma GJ et al.: Telomerase in (pre) neoplastic cervical disease. Hum. Pathol. 31(10), 1304-1312 (2000).
100. Wisman GB, Knol AJ, Helder MN et al.: Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer. Int. J. Cancer 91(5), 658-664 (2001).
101. Anderson S, Shera K, Ihle J et al.: Telomerase activation in cervical cancer. Am. J. Patbol. 151(1), 25-31 (1997).
102. Wisman GB, Hollema H, de Jong S et al.: Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear. J. Clin. Oncol. 16(6), 2238-2245 (1998).
103. Yashima K, Ashfaq R, Nowak J et al.: Telomerase activity and expression of its RNA component in cervical lesions. Cancer 82(7), 1319-1327 (1998).
104. Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Tamaya T. Telomerase activity in the female reproductive tract and neoplasms. Gynecol. Oncol. 68(2), 145-149 (1998).
105. Zhang DK, Ngan HY, Cheng RY, Cheung AN, Liu SS, Tsao SW: Clinical significance of telomerase activation and telomeric restriction fragment (TRF) in cervical cancer. Eur. J. Cancer 35(1). 154-160 (1998).
106. Jarboe EA, Liaw KL, Diompson LC et al.: Analysis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma. Oncogene 21(4), 664-673 (2002).